Sobi's Upcoming Showcase at ASH 2024
Sobi®, a leading biopharmaceutical company, is gearing up to unveil important new data at the 66th Annual Meeting of the American Society of Hematology (ASH) in December 2024. This event will gather experts and research enthusiasts to discuss advancements in hematology, particularly focusing on diseases such as haemophilia A, hemophagocytic lymphohistiocytosis (HLH), myelofibrosis, paroxysmal nocturnal hemoglobinuria (PNH), and immune thrombocytopenia (ITP).
Advancements in Haemophilia A Treatment
According to Lydia Abad-Franch, MD, MBA, Head of Research, Development, and Medical Affairs at Sobi, the presentations will spotlight pivotal findings related to haemophilia A. The highlights include three oral presentations centered on the long-term outcomes associated with ALTUVOCT® prophylaxis. These revelations emphasize the significant impact of haemophilia A on joint health and overall quality of life, underscoring Sobi's commitment to innovative therapies.
Key Presentations to Expect
The conference will display several key analyses. One prominent oral presentation will explore the association between the Hemophilia Joint Health Score and quality of life, integrating findings from the XTEND-1 trial. Additionally, Sobi will share results from a phase 3 long-term extension study investigating clinical outcomes of Efanesoctocog Alfa— the active component in ALTUVOCT — after three years of treatment in adults and adolescents with severe haemophilia A.
Understanding Real-World Effectiveness
Another significant presentation will evaluate the real-world experience patients have had when transitioning to prophylactic Efanesoctocog Alfa. This will shed light on how these treatments perform outside of clinical trial settings, providing valuable insights into patient responses and treatment efficacy.
Addressing Other Rare Blood Disorders
In addition to haemophilia A, Sobi's findings at ASH 2024 will address a variety of severe and rare diseases. Presentations will cover innovative analyses and real-world data related to Doptelet® and Gamifant® therapies, demonstrating Sobi's broad commitment to advancing treatments for numerous haematological conditions.
Providing Comprehensive Care
Sobi’s ongoing research extends into treating HLH, with new data on the use of Gamifant exploring transplant-related outcomes in patients. Furthermore, the efficacy of Vonjo® in managing myelofibrosis and real-world clinical outcomes for PNH patients treated with Aspaveli® will also be presented.
Looking Ahead to the Future of Haematology
The upcoming ASH 2024 meeting promises to be a remarkable event, driving discussions about the future of treatment in blood disorders. With a lineup of essential presentations, the event will not only showcase Sobi's innovations but also contribute to a broader understanding of treatment protocols and patient care strategies in the field of haematology.
About Sobi®
Sobi® is dedicated to transforming the lives of individuals facing rare and debilitating diseases. With a strong portfolio in hematology and a commitment to providing innovative therapies, Sobi has established a global presence and continues to pursue advancements that enhance patient care. The company operates worldwide, with a significant focus on creating reliable access to life-changing medicines.
Frequently Asked Questions
What is the focus of Sobi's presentations at ASH 2024?
Sobi will present new data on various hematological conditions, focusing extensively on haemophilia A and other rare blood disorders.
Who is speaking on behalf of Sobi at the conference?
Lydia Abad-Franch, MD, MBA, will represent Sobi and present key findings regarding treatment advancements.
What new data will be presented about ALTUVOCT®?
New data on the long-term outcomes of ALTUVOCT® prophylaxis in haemophilia A patients will be shared, emphasizing its effectiveness and impact on joint health.
Why is the ASH conference important for Sobi?
The ASH conference is crucial for Sobi as it allows the company to share significant research findings that can influence treatment strategies and improve patient outcomes.
How can I learn more about Sobi's products?
For more information on Sobi’s products and innovations, you can visit their official website.
